Biomateriais para formulações de base nanotecnológica visando terapia gênica ocular

Zorzi, Giovanni K.; Schuh, Roselena Silvestri; Campos, Angela Machado de; Carvalho, Edison Luis Santana; Rott, Marilise Brittes; Teixeira, Hélder Ferreira

doi:10.21577/0100-4042.20160151

Cited by 4 publications

(4 citation statements)

References 117 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, compounds with high molecular weight (above 500 Da) cross a membrane with difficulty, the lower the molecular weight is, the easier the compound crosses a lipid membrane. 40 CPA (positive control in this study), with 416.94 Da of molecular weight, shows rapid and almost total absorption in the body. Examples such as vancomycin, with a molecular weight of 1250 Da, also illustrates that reported above, because this drug does not present significant absorption when administered orally.…”

Section: Pharmacokinetic and Toxicity Predictions Studiesmentioning

confidence: 76%

Ligand- and structure-based virtual screening from 16-((diisobutylamino)methyl)-6α-hydroxyivouacapane-7β,17β-lactone a compound with potential anti-prostate cancer activity

Silva

Poiani

Ramos

et al. 2019

JSCS

View full text Add to dashboard Cite

Prostate cancer is one of the leading causes of disease and death on the planet. The probable bioactive pose of 16-((diisobutylamino)methyl)-6α-hydroxyvouacapane-7β,17β-lactone (N,N-DHL), a pivot compound with prostatic anti-cancer activity, was investigated via a semi-empirical method (PM3) and refined with the base set 6-31+G(d,p) calculated in the DFT method at the B3LYP level of theory. This structure was used in ligand-based virtual screening for five commercial compound bases using the software ROCS and EON that selected 2000 per base and another that resulted in 100 per base, respectively. This set was used for pharmacokinetic and toxicological predictions. The molecular overlap index at 50 % steric/electrostatic provided 68 structures that were used for a molecular docking study. The results showed that of 238,922 structures, only eight, 7 (-10.9 kcal mol-1) as the best in the series and 1 (-8.1 kcal mol-1) as less favorable, with others in this range (±2.8 kcal mol-1) with their respective binding affinity: 8 (-8.2 kcal mol-1), 5 (-8.2 kcal mol-1), 4 (-8.3 kcal mol-1), 2 (-8.5 kcal mol-1), 3 (-8.6 kcal mol-1) and 6 (-8.8 kcal mol-1) remaining in the final selection. The predictions for 21 pharmacokinetic properties were within the recommended range, similar to 95 % of the drugs available on the market, with no toxicity warning. The structures showed similarity greater than 75 % to the pivot based on binding affinity and predictions but only the structures 6 and 7 were considered more promising for their potential anti-prostate cancer activity (PC-3).

show abstract

Section: Pharmacokinetic and Toxicity Predictions Studiesmentioning

confidence: 76%

Ligand- and structure-based virtual screening from 16-((diisobutylamino)methyl)-6α-hydroxyivouacapane-7β,17β-lactone a compound with potential anti-prostate cancer activity

Silva

Poiani

Ramos

et al. 2019

JSCS

View full text Add to dashboard Cite

show abstract

“…Unfortunately, anti‐VEGF antibodies are generally limited due to their poor efficacy, side effects, and drug resistance 7 . RNA interference is a powerful approach to knocking down target genes 17 . VEGF small interfering RNA (siVEGF) reduces VEGF expression and CNV 18–21 .…”

Section: Introductionmentioning

confidence: 99%

“…7 RNA interference is a powerful approach to knocking down target genes. 17 VEGF small interfering RNA (siVEGF) reduces VEGF expression and CNV. [18][19][20][21] Accordingly, it is reasonable to speculate that siVEGF could enhance the therapeutic effects of INS on corneal alkali injury, and codelivery of INS and siVEGF may provide a new combination therapy for corneal alkali injury.…”

mentioning

confidence: 99%

Liposome–trimethyl chitosan nanoparticles codeliver insulin and siVEGF to treat corneal alkali burns by inhibiting ferroptosis

Xiong

Jiang

Liao

et al. 2023

Bioengineering & Transla Med

View full text Add to dashboard Cite

Alkali burns are potentially blinding corneal injuries. Due to the lack of available effective therapies, the prognosis is poor. Thus, effective treatment methods for corneal alkali burns are urgently needed. Codelivery nanoparticles (NPs) with characteristics such as high bioavailability and few side effects have been considered effective therapeutic agents for ocular diseases. In this study, we designed a new combination therapy using liposomes and trimethyl chitosan (TMC) for the codelivery of insulin (INS) and vascular endothelial growth factor small interfering RNA (siVEGF) to treat alkali-burned corneas. We describe the preparation and characterization of siVEGF-TMC-INS-liposome (siVEGF-TIL), drug release characteristics, intraocular tracing, pharmacodynamics, and biosafety. We found that siVEGF-TIL could inhibit oxidative stress, inflammation, and the expression of VEGF in vitro and effectively maintained corneal transparency, accelerated epithelialization, and inhibited corneal neovascularization (CNV) in vivo. Morever, we found that the therapeutic mechanism of siVEGF-TIL is possibly relevant to the inhibition of the ferroptosis signaling pathway by metabolomic analysis. In general, siVEGF-TIL NPs could be a safe and effective therapy for corneal alkali burn.

show abstract

“…Nanotechnology can be used to protect molecules that have physicochemical limitations, including nanoencapsulation with polymers, which can help reduce volatilization and increase effectiveness [ 20 ]. These polymeric nanocapsules are carrier systems with a diameter of less than 1000 nm, a polymeric wall, and an oily core where the desired drugs or bioactive compounds can be inserted [ 21 , 22 , 23 , 24 , 25 ].…”

Section: Introductionmentioning

confidence: 99%

Polymeric Nanorepellent Systems Containing Geraniol and Icaridin Aimed at Repelling Aedes aegypti

Andrade

Guilger-Casagrande

Germano-Costa

et al. 2022

IJMS

View full text Add to dashboard Cite

Repellents are among the leading products used against diseases transmitted by the Aedes aegypti mosquito. However, their indiscriminate use or high concentrations can cause severe adverse reactions, particularly in children and pregnant women. To protect them, nanotechnology is a promising tool to encapsulate active compounds against degradation, increase their effectiveness, and decrease their toxicity, as it can promote the modified release of the active compound. This study aimed to develop polymeric nanocapsules containing the repellent actives geraniol and icaridin using low concentrations of the active component, with the objective of promoting effective activity and greater safety against adverse reactions. The nanocapsules were developed by the interfacial deposition method, and the physicochemical properties of the nanocapsules were evaluated using dynamic light scattering (DLS), nanoparticle tracking analysis (NTA), zeta potential, differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FTIR), atomic force microscopy (AFM), release kinetics assay, and mathematical modeling. Cell viability was assessed by the MTT assay and genotoxicity analysis using the comet assay. The developed nanocapsules containing geraniol and icaridin showed mean diameters of 260 nm and 314 nm, respectively, with a polydispersity index < 0.2. The nanocapsules showed encapsulation efficiency values of 73.7 ± 0.1% for icaridin and 98.7 ± 0.1% for geraniol. Morphological analysis showed spherical nanocapsules with low polydispersity. The kinetic parameters calculated using the Korsmeyer–Peppas model indicated an anomalous release profile. Cell viability and genotoxicity analyses showed that the nanocapsules did not alter cell viability or damage DNA. The results demonstrate a promising nanostructured system with good physicochemical characteristics and good stability, with repellent activity against Aedes aegypti.

show abstract

Biomateriais para formulações de base nanotecnológica visando terapia gênica ocular

Cited by 4 publications

References 117 publications

Ligand- and structure-based virtual screening from 16-((diisobutylamino)methyl)-6α-hydroxyivouacapane-7β,17β-lactone a compound with potential anti-prostate cancer activity

Ligand- and structure-based virtual screening from 16-((diisobutylamino)methyl)-6α-hydroxyivouacapane-7β,17β-lactone a compound with potential anti-prostate cancer activity

Liposome–trimethyl chitosan nanoparticles codeliver insulin and siVEGF to treat corneal alkali burns by inhibiting ferroptosis

Polymeric Nanorepellent Systems Containing Geraniol and Icaridin Aimed at Repelling Aedes aegypti

Contact Info

Product

Resources

About